NCT00474266 - Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children | Biotech Hunter

Enrollment

1,000

Participants

Timeline

Start Date

June 5, 2007

Primary Completion Date

February 26, 2008

Study Completion Date

March 26, 2008

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL

Meningococcal vaccine GSK134612 (Nimenrix)

Single dose intramuscular injection

BIOLOGICAL

Priorix-Tetra

2-dose subcutaneous injection

BIOLOGICAL

Meningitec

Single dose intramuscular injection

Trial Locations (14)

15140

GSK Investigational Site, Lahti

20520

GSK Investigational Site, Turku

28100

GSK Investigational Site, Pori

33100

GSK Investigational Site, Tampere

48600

GSK Investigational Site, Kotka

60100

GSK Investigational Site, Seinäjoki

70100

GSK Investigational Site, Kuopio

90100

GSK Investigational Site, Oulu

02100

GSK Investigational Site, Espoo

00100

GSK Investigational Site, Helsinki

00930

GSK Investigational Site, Helsinki

04400

GSK Investigational Site, Järvenpää

01300

GSK Investigational Site, Vantaa

01600

GSK Investigational Site, Vantaa